The tweet was deleted by the author.
But we saved everything 🙂.
Atossa Therapeutics, Inc. recently hosted a virtual Key Opinion Leader (KOL) event titled Endoxifen Role in Breast Cancer, bringing expert focus to the development of (Z)-endoxifen for ER positive breast cancer patients.
The session featured Dr. Laura Esserman in an in-depth discussion about (Z)-endoxifen's clinical potential and was moderated by Michael King from Rodman & Renshaw. The event explored ongoing research directions and highlighted the importance of new therapies in breast cancer treatment. Further details can be found at the provided link.
Atossa previously announced plans for a virtual KOL event to examine Z-endoxifen as an endocrine therapy for breast cancer. The company also secured FDA rare pediatric disease designation for (Z)-endoxifen in McCune-Albright syndrome. These steps mark ongoing advances in Atossa’s clinical programs.